ReviewCell biology and toxicology2026
The m6A-circRNA axis: a therapeutic prospect for gastric cancer.
Review in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gastric cancer (GC) remains a major global health burden, and resistance to conventional therapies continues to limit durable clinical benefit. Increasing evidence identifies the N6-methyladenosine (m6A)-circular RNAs (circRNAs) axis as a critical regulatory network driving GC progression and therapeutic resistance. The functional interplay between m6A RNA modification and circRNAs contributes to key oncogenic processes, including chemoresistance, immune evasion, metabolic reprogramming, and resistance to cell death. In particular, m6A-modified circRNAs promote tumor progression by enhancing transcript stability, facilitating oncogenic signaling, modulating immune checkpoint pathways, and supporting metabolic adaptation under therapeutic stress. In this review, we synthesize current advances in understanding the mechanistic and translational significance of the m6A-circRNA axis in GC. We examine how this regulatory interface orchestrates adaptive resistance and evaluate emerging therapeutic strategies aimed at targeting its components. Modulating the m6A-circRNA axis-either as a standalone approach or in combination with existing treatments-represents a promising strategy to overcome multidrug resistance and improve clinical outcomes in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.